67560-68-3

Basic information

• Product Name: Lariciresil dimethyl ether
• Synonyms: Lariciresil dimethyl ether;Lariciresinol diMethyl ether
• CAS NO: 67560-68-3
• Molecular Formula: C₂₂H₂₈O₆
• Molecular Weight: 388.45412
• Mol File: 67560-68-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 528.4°Cat760mmHg
• Flash Point: 273.4°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 5.38E-12mmHg at 25°C
• Refractive Index: 1.545
• CAS DataBase Reference: Lariciresil dimethyl ether(CAS DataBase Reference)
• NIST Chemistry Reference: Lariciresil dimethyl ether(67560-68-3)
• EPA Substance Registry System: Lariciresil dimethyl ether(67560-68-3)

Safety Data

• Hazardous Substances Data: 67560-68-3(Hazardous Substances Data)

Usage

General Description

Lariciresinol dimethyl ether is a chemical compound derived from the lignan lariciresinol found in various plants, including flaxseed and sesame. It is categorized as a phenylpropanoid and is known for its antioxidant and anti-inflammatory properties. Research has shown that lariciresinol dimethyl ether has potential therapeutic benefits for conditions such as diabetes, cardiovascular disease, and cancer. Additionally, it has also been studied for its potential as a natural preservative in food products due to its antimicrobial properties. Overall, lariciresinol dimethyl ether is a promising compound with a wide range of potential applications in both the pharmaceutical and food industries.

InChI:InChI=1/C22H28O6/c1-24-18-7-5-14(10-20(18)26-3)9-16-13-28-22(17(16)12-23)15-6-8-19(25-2)21(11-15)27-4/h5-8,10-11,16-17,22-23H,9,12-13H2,1-4H3/t16-,17-,22+/m0/s1

Upstream product

• 5460-32-2 1-iodo-3,4-dimethoxybenzene 
• 872853-94-6 (S)-1-(3',4'-dimethoxyphenyl)prop-2-en-1-ol 
• 203924-93-0 1-(3,4-dimethoxyphenyl)-2,3-epoxypropan-1-ol 
• 31706-95-3 1'-Hydroxymethyleugenol 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 186581-53-3 diazomethane 
• 486-29-3 lariciresinol 
• 526-06-7 eudesmin 

Relevant articles and documents

A LIGNAN FROM ACTINODAPHNE LONGIFOLIA

A new lignan, actifolin, was isolated from the leaves of Actinodaphne longifolia and the structure was established on the basis of chemical and spectroscopic evidence.Key Word Index - Actinodaphne longifolia; Lauraceae; lignan; actifolin; piperitol.

Design and synthesis of a compound library exploiting 5-methoxyleoligin as potential cholesterol efflux promoter

5-Methoxyleoligin and leoligin are natural occurring lignans derived from Edelweiss (Leontopodium nivale ssp. alpinum), displaying potent pro-angiogenic and pro-arteriogenic activity. Cholesterol efflux from macrophages is associated with reverse cholesterol transport which inhibits the development of cardiovascular disease. Within this study, we developed a modular and stereoselective total synthesis of 5-methoxyleoligin which can be readily used to prepare a novel compound library of related analogs. The target 5-methoxyleoligin was synthesized exploiting a recently disclosed modular route, which allows also rapid synthesis of analogous compounds. All obtained products were tested towards macrophage cholesterol efflux enhancement and the performance was compared to the parent compound leoligin. It was found that variation on the aryl moiety in 2-position of the furan ring allows optimization of the activity profile, whereas the ester-functionality does not tolerate significant alterations.

PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES

The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl) -2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.